Table 1.
Patient medical history
| Treatment line | Start and stop, year/month | Sites of metastasis | Therapeutic schedule | Best response | TTP (months) |
|---|---|---|---|---|---|
| 1st | 1996/ to 1997/3 | Lung | Paclitaxel 80 mg/m2 weekly (day 1–8–15, w4) | PR | 12 |
| 2nd | 1997/4 to 2000/1 | Lung | Megestrol 160 mg dailya | PR | 33 |
| 3rd | 2000/1 to 2001/1 | Lung | Exemestane 25 mg daily | SD | 12 |
| 4th | 2001/2 to 2001/6 | Lung | Epirubicin (75 mg/mq day1) and Docetaxel (80 mg/mq day1) w3a | SD | 4 |
| 5th | 2001/7 to 2002/1 | Lung | Letrozole (2.5 mg daily) and LHRHa | PD | 6 |
| 6th | 2002/2 to 2002/12 | Lung | Vinorelbine 25 mg/m2 IV day 1–>5 w3 | PD | 10 |
| 7th | 2002/12 to 2007/10 | Lung | Megestrol 160 mg dailyb | PR | 58 |
| 8th | 2007/10 to 2008/5 | Lung | Tamoxifen 20 mg daily | PR | 7 |
| 2008/6 to 2009/1 | No therapy | ||||
| 9th | 2009/1 to 2011/2 | Lung | Capecitabine 1000 mg/mq b.i.d. from days 1 to 14, w3 | SD | 25 |
| 10th | 2011/2 to 2013/3 | Lung | Cyclophosphamide 50 mg/die PO and Methotrexate 2, 5 mg PO twice a week | SD | 25 |
| 2013/4 | Lung, bone | Palliative radiant treatment for bone metastases of sacral spine. | |||
| 11th | 2013/5 to 2013/10 | Lung, bone, nodes | Carboplatinum (AUC5) w3, Zoledronic acid | PD | 5 |
| 12th | 2013/10 to 2014/4 | Lung, bone, nodes, subcutaneous | Eribuline 1.2 mg/m2 day 1–8 w3c Zoledronic Acid | PD | 6 |
| 13th | 2014/5 to 2014/9 | Lung, bone, nodes, subcutaneous | Everolimus 10 (5) mg daily and Exemestane 25 mg dailyd | PR | 4 |
TTP time to progression, PR partial response, SD stationarity of disease, PD progression of disease, LHRHa Luteinizing hormone releasing hormone (LHRH) agonist
aPoor tolerance
bRechallenge
cPulmunary thromboembolism
dDeterioration of clinical condition